New Partnership Introduces Advanced Drug Residue Testing Technology to Canadian Market
TL;DR
Gain an edge in drug residue detection with the Unow™ Device, providing rapid, accurate results for law enforcement and healthcare.
The Unow™ Drug Residue Test Device utilizes advanced diagnostic technology to swiftly identify hazardous residues in public spaces and healthcare settings.
The partnership between Taizhou Kaimi Biotech and Scenesafe aims to enhance community safety by introducing the Unow™ Device for reliable drug contamination detection.
Discover the cutting-edge Unow™ Device, a portable testing solution that revolutionizes drug residue detection with laboratory-grade accuracy in minutes.
Found this article helpful?
Share it with your network and spread the knowledge!

The strategic partnership between Taizhou Kaimi Biotech and Scenesafe Trauma Scene Remediation introduces the Unow™ Drug Residue Test Device to the Canadian market, representing a significant advancement in portable detection technology. This innovative solution provides laboratory-grade identification of trace amounts of hazardous substances including opioids, fentanyl, and methamphetamine through rapid on-site testing capabilities. The technology addresses critical safety concerns across multiple sectors by enabling swift detection without requiring laboratory analysis.
The Unow™ device serves law enforcement investigations by providing immediate results during drug-related crime scene examinations. Healthcare facilities benefit from the technology's ability to ensure sterile environments and prevent cross-contamination in medical settings. Remediation teams can validate decontamination efforts with precise measurements, while residential and commercial property owners gain assurance about the safety of their spaces. The portable nature of the device allows for immediate testing in various environments without compromising accuracy.
Otis Zhao, President and Founder of Taizhou Kaimi Biotech, emphasized the technology's community protection potential, noting that the partnership with Scenesafe ensures the solution meets specific Canadian market requirements. Hang Ai, Founder of Scenesafe, highlighted the device's significance in addressing drug contamination risks for first responders, families, and businesses. The collaboration combines Taizhou Kaimi Biotech's biotech innovation expertise with Scenesafe's comprehensive understanding of Canadian safety protocols to establish new standards in drug residue detection and remediation.
The Unow™ Drug Residue Test Device is scheduled for availability to Canadian clients in the second quarter of 2025, with pre-orders anticipated to open soon. This technology represents a substantial improvement over traditional testing methods by providing immediate, reliable results in field conditions. The partnership demonstrates how specialized expertise from different sectors can combine to create solutions that address complex public safety challenges while meeting regulatory requirements and operational needs across multiple industries.
Curated from 24-7 Press Release
